UA66417C2 - Recombinant adenovirus affecting canines, pharmaceutical composition - Google Patents

Recombinant adenovirus affecting canines, pharmaceutical composition

Info

Publication number
UA66417C2
UA66417C2 UA95114778A UA95114778A UA66417C2 UA 66417 C2 UA66417 C2 UA 66417C2 UA 95114778 A UA95114778 A UA 95114778A UA 95114778 A UA95114778 A UA 95114778A UA 66417 C2 UA66417 C2 UA 66417C2
Authority
UA
Ukraine
Prior art keywords
canines
affecting
pharmaceutical composition
recombinant adenovirus
adenovirus
Prior art date
Application number
UA95114778A
Other languages
English (en)
Original Assignee
Gencell Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9447235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA66417(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gencell Sa filed Critical Gencell Sa
Publication of UA66417C2 publication Critical patent/UA66417C2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UA95114778A 1993-05-18 1994-05-06 Recombinant adenovirus affecting canines, pharmaceutical composition UA66417C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9305954A FR2705361B1 (fr) 1993-05-18 1993-05-18 Vecteurs viraux et utilisation en thérapie génique.
PCT/FR1994/000531 WO1994026914A1 (fr) 1993-05-18 1994-05-06 Vecteurs adenoviraux d'origine animale et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
UA66417C2 true UA66417C2 (en) 2004-05-17

Family

ID=9447235

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95114778A UA66417C2 (en) 1993-05-18 1994-05-06 Recombinant adenovirus affecting canines, pharmaceutical composition

Country Status (26)

Country Link
US (1) US6294377B1 (xx)
EP (1) EP0698108B2 (xx)
JP (2) JP3995259B2 (xx)
KR (1) KR100379569B1 (xx)
CN (1) CN1067722C (xx)
AT (1) ATE209686T1 (xx)
AU (1) AU696495B2 (xx)
BR (1) BR9406720A (xx)
CA (1) CA2163256C (xx)
CZ (1) CZ284903B6 (xx)
DE (1) DE69429260T3 (xx)
DK (1) DK0698108T4 (xx)
ES (1) ES2167365T5 (xx)
FI (1) FI118538B (xx)
FR (1) FR2705361B1 (xx)
HU (1) HU221340B1 (xx)
IL (1) IL109644A (xx)
NO (1) NO320818B1 (xx)
NZ (1) NZ266475A (xx)
PL (1) PL182814B1 (xx)
PT (1) PT698108E (xx)
RU (1) RU2233333C2 (xx)
SK (1) SK282354B6 (xx)
UA (1) UA66417C2 (xx)
WO (1) WO1994026914A1 (xx)
ZA (1) ZA943358B (xx)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU663702B2 (en) 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2740344B1 (fr) * 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers
DE69740033D1 (de) * 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
AU4255397A (en) * 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
HUP0002922A3 (en) 1997-04-28 2003-03-28 Aventis Pharma Sa Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
ATE374247T1 (de) 1997-10-14 2007-10-15 Darwin Molecular Corp Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US6653088B1 (en) 1997-10-24 2003-11-25 Aventis Pharma S.A. Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
ZA99133B (en) 1998-01-08 1999-09-16 Rhone Poulenc Rorer Pharma Transgenic rabbit that expresses a functional human lipoprotein (A).
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
CA2339409A1 (en) 1998-08-11 2000-02-24 Darwin Discovery Ltd. Identification of the gene causing the mouse scurfy phenotype and its human ortholog
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
EP1255822A2 (en) * 1999-12-27 2002-11-13 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
AU784349C (en) 2000-01-12 2006-09-28 Yale University Nogo receptor-mediated blockade of axonal growth
CN1430505A (zh) 2000-03-24 2003-07-16 生物领域医疗公司 用于主动栓塞术的微球体
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
CN100422210C (zh) 2000-12-28 2008-10-01 Wyeth公司 来自肺炎链球菌的重组防护蛋白质
EP1967525B1 (en) 2001-05-08 2012-11-14 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US7582425B2 (en) 2001-09-21 2009-09-01 The Regents Of The University Of Michigan Atlastin
US7108975B2 (en) 2001-09-21 2006-09-19 Regents Of The University Of Michigan Atlastin
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2464527A1 (en) 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CA2484000A1 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
FR2845395B1 (fr) * 2002-10-08 2008-05-30 Agronomique Inst Nat Rech Vecteurs adenoviraux recombinants et leurs applications
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
RU2448157C2 (ru) 2004-05-26 2012-04-20 Псиоксус Терапьютикс Лимитед Химерные аденовирусы для применения для лечения злокачественного новообразования
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
WO2006020071A2 (en) 2004-07-16 2006-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccines against aids comprising cmv/r-nucleic acid constructs
US10000757B2 (en) 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector
AU2007217366A1 (en) 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
MX2009000976A (es) 2006-07-28 2009-03-09 Sanofi Aventis Composicion y metodo para el tratamiento de tumores.
EP2829551B1 (en) 2006-10-19 2017-12-13 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
EP2068922B1 (en) 2006-10-19 2012-06-27 CSL Limited Anti-il-13r alpha 1 antibodies and their uses thereof
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2231164A1 (en) 2007-12-03 2010-09-29 The Regents of the University of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
KR20110081282A (ko) 2008-11-05 2011-07-13 와이어쓰 엘엘씨 베타―용혈성 연쇄구균 (ｂｈｓ) 질환의 예방을 위한 다성분 면역원성 조성물
EP2373338B1 (en) 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 as immunological target
JP6091752B2 (ja) * 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US9186370B2 (en) 2010-03-19 2015-11-17 University Of South Alabama Methods and compositions for the treatment of cancer
EP3299464B1 (en) * 2010-05-26 2019-10-02 CuRNA, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
US9771579B2 (en) * 2010-06-23 2017-09-26 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
US9458456B2 (en) 2011-04-01 2016-10-04 University Of South Alabama Methods and compositions for the diagnosis, classification, and treatment of cancer
WO2013103401A1 (en) 2012-01-06 2013-07-11 University Of South Alabama Methods and compositions for the treatment of cancer
CN104334187B (zh) 2012-03-09 2017-04-05 辉瑞公司 脑膜炎双球菌组合物及其方法
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6262723B2 (ja) 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
EP2946016A4 (en) * 2013-01-15 2016-11-23 Univ California ADENOVIRUS AND THEIR USE
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
CN105263500A (zh) 2013-05-02 2016-01-20 加利福尼亚大学董事会 骨选择性成骨性氧固醇-骨靶向剂
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
NZ718931A (en) 2013-10-25 2022-10-28 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
EP3107939B1 (en) 2014-02-19 2020-06-17 University of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
PT3159409T (pt) 2014-06-17 2020-01-21 Nippon Shinyaku Co Ltd Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
EP3250279B1 (en) 2015-01-30 2020-08-19 The Regents of the University of California Spinal subpial gene delivery system
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
EP3288573B1 (en) 2015-04-30 2020-02-12 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
WO2017070237A1 (en) 2015-10-19 2017-04-27 University Of Maryland, Baltimore Methods for generating engineered human primary blood dendritic cell lines
EP3389682B1 (en) 2015-12-17 2021-11-17 Psioxus Therapeutics Limited Group b adenovirus encoding an anti-tcr-complex antibody or fragment
US11472859B2 (en) 2016-03-28 2022-10-18 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitabtiity
US11560412B2 (en) 2016-04-01 2023-01-24 University Of Maryland, Baltimore Compositions comprising GRIM-19 therapeutics and methods of use
AU2017254665C1 (en) 2016-04-20 2021-03-11 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Compositions and methods for enhanced gene expression of PKLR
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3503918B1 (en) 2016-08-29 2020-09-30 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
AU2017329654B2 (en) 2016-09-20 2024-04-04 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
TW201823467A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 犬腺病毒載體
AR109539A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Sitio de inserción orf70 de ehv
MX2019003160A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevos promotores.
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
WO2019079338A1 (en) 2017-10-16 2019-04-25 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. LENTIVIRAL VECTORS FOR PKLR ADMINISTRATION TO TREAT PYRUVATE KINASE DEFICIENCY
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
JP2021529513A (ja) 2018-07-02 2021-11-04 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症および脊髄に関連する障害の治療
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
EP4192487A1 (en) 2020-08-07 2023-06-14 Spacecraft Seven, LLC Plakophilin-2 (pkp2) gene therapy using aav vector
MX2023012608A (es) 2021-04-30 2023-11-03 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc.
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
WO2023081633A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU670933B2 (en) * 1992-03-27 1996-08-08 Collimore Enterprises Pty Ltd Formwork device

Also Published As

Publication number Publication date
EP0698108B2 (fr) 2005-12-21
DE69429260T2 (de) 2002-07-04
KR100379569B1 (ko) 2004-03-06
CZ302895A3 (en) 1996-02-14
IL109644A0 (en) 1994-08-26
AU696495B2 (en) 1998-09-10
JPH08510122A (ja) 1996-10-29
PL311660A1 (en) 1996-03-04
ES2167365T5 (es) 2006-08-16
DK0698108T3 (da) 2002-02-11
CN1067722C (zh) 2001-06-27
NO954466D0 (no) 1995-11-07
FR2705361B1 (fr) 1995-08-04
FI955552A (fi) 1995-12-27
HUT73465A (en) 1996-08-28
EP0698108B1 (fr) 2001-11-28
JP3995259B2 (ja) 2007-10-24
IL109644A (en) 2005-06-19
CA2163256A1 (fr) 1994-11-24
NO954466L (no) 1995-11-07
CA2163256C (fr) 2008-09-23
WO1994026914A1 (fr) 1994-11-24
DE69429260T3 (de) 2006-08-03
NZ266475A (en) 2000-04-28
US6294377B1 (en) 2001-09-25
EP0698108A1 (fr) 1996-02-28
NO320818B1 (no) 2006-01-30
AU6787894A (en) 1994-12-12
CZ284903B6 (cs) 1999-04-14
PL182814B1 (pl) 2002-03-29
ES2167365T3 (es) 2002-05-16
SK144795A3 (en) 1996-04-03
DE69429260D1 (de) 2002-01-10
FI955552A0 (fi) 1995-11-17
CN1124040A (zh) 1996-06-05
KR960702525A (ko) 1996-04-27
RU2233333C2 (ru) 2004-07-27
HU221340B1 (en) 2002-09-28
ZA943358B (en) 1995-01-16
PT698108E (pt) 2002-04-29
ATE209686T1 (de) 2001-12-15
FR2705361A1 (fr) 1994-11-25
HU9503297D0 (en) 1996-01-29
SK282354B6 (sk) 2002-01-07
FI118538B (fi) 2007-12-14
JP2004180689A (ja) 2004-07-02
BR9406720A (pt) 1996-02-06
DK0698108T4 (da) 2006-04-18

Similar Documents

Publication Publication Date Title
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
GR3030130T3 (en) Asp b28 insulin crystals
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
BR9405507A (pt) Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
YU29901A (sh) Primena dialkil fumarata
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
GR3031354T3 (en) Soluble interferon -receptor, its preparation and use.
AU4378996A (en) Cell compositions for use in transplantation and ex vivo gene therapy
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
NZ503401A (en) Use of interferon-beta (IFN-B) genes for the treatment of cancer
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
HU9600432D0 (en) Novel tripeptides useful in immune and cns therapy
ATE311886T1 (de) Verwendung einer zusammensetzung enthaltend 5- androsten-3beta,17alpha-diol
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
ZA887950B (en) Human t-pa(u-pa)substitution-mutant proteins,recombinant dna coding therefor,transfected host cells,preparation of the mutant proteins,and pharmaceutical compositions
IL88173A0 (en) Human t-pa(u-pa)substitution-mutant proteins,recombinant dna coding therefor,transfected host cells,preparation of the mutant proteins,and pharmaceutical compositions
AU2438688A (en) Human t-pa(u-pa) substitution-mutant proteins, recombinant dna coding therefor, transfected host cells, preparation of the mutant proteins, and pharmaceutical compositions
MX9801920A (es) Composicion farmaceutica util para la transfeccion de acidos nucleicos y sus usos.
MY103637A (en) Neutrophil-activating factor